Dreyling M et al. TRIANGLE: Autologous transplantation after rituximab/ibrutinib/ara-c containing induction in generalized mantle cell lymphoma – a randomized European MCL network trial. Blood 2019;134(Supplement_1):2816. Abstract

Jain P et al. Acalabrutinib with rituximab as first-line therapy for older patients (≥65) with mantle cell lymphoma – A phase II clinical trial. ICML 2023;Abstract 099.

Palomba ML et al. Safety and preliminary efficacy in patients with relapsed/refractory mantle cell lymphoma receiving lisocabtagene maraleucel in transcend NHL 001. ASH 2020;Abstract 118.

Phillips TJ et al. Glofitamab monotherapy induces high complete response rates in patients with heavily pretreated relapsed or refractory mantle cell lymphoma. ASH 2022;Abstract 74.

Thompson PA, Tam CS. Pirtobrutinib: A new hope for patients with BTK inhibitor-refractory lymphoproliferative disorders. Blood 2023;141(26):3137-42. Abstract

Wang M et al. BRUIN MCL-321: A phase 3, open-label, randomized study of pirtobrutinib versus investigator choice of BTK inhibitor in patients with previously treated, BTK inhibitor naïve mantle cell lymphoma. ASCO 2023;Abstract TPS7587.

Wang M et al. Pirtobrutinib in covalent Bruton tyrosine kinase inhibitors pretreated mantle-cell lymphoma. J Clin Oncol 2023;41(24):3988-97. Abstract

Wang M et al. Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups in the ZUMA-2 study. J Clin Oncol 2023;41(3):555-67. Abstract

Wang M et al. Acalabrutinib plus venetoclax and rituximab in patients with treatment-naïve mantle cell lymphoma: 2-year safety and efficacy analysis. Blood 2022;140(Supplement 1):6477-9. Abstract

Wang M et al. Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N Engl J Med 2022;386(26):2482-94. Abstract